Psoriasis

Taiwanese patients with psoriasis were found to be at greater risk of developing gout; nonsteroidal anti-inflammatory drug use was shown to decrease such risk.

The study called for increased education, productive health care professional dialogue, and shared decision-making in the management of patients with psoriasis and psoriatic arthritis.

Cardiac troponin I (cTnI) and N-terminal pro-brain-type natriuretic peptide (NT-proBNP) were associated with incident cardiovascular events in patients with psoriatic disease.

Soumya Chakravarty, MD, PhD, FACP, FACR, strategic lead, Rheumatology Therapeutic Area at Janssen, spoke on adverse patient outcomes caused by diagnostic delays in psoriatic arthritis and progress made to address this unmet need.

Japanese patients with psoriasis reported improved objective symptoms and satisfaction with brodalumab.

Soumya Chakravarty, MD, PhD, FACP, FACR, strategic lead of the Rheumatology Therapeutic Area at Janssen, discussed the interlinked pathophysiology of psoriasis and psoriatic arthritis, and the involvement of inflammatory mediators for both conditions.

Clinical response to ustekinumab for patients with psoriasis was shown to vary by body region, in which lower extremities were identified as the most difficult to treat.

Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, discusses considerations to address unmet needs and identify appropriate treatment of patients with pustular psoriasis.

Adalimumab and infliximab were the most common biologic therapies associated with the onset of palmoplantar pustulosis and palmoplantar pustular psoriasis.

A JAMA Dermatology study found that greater exposure to air pollutants, such as carbon monoxide and fine particulate matter, were significantly associated with later psoriasis flares.

Risankizumab was shown to be highly effective in patients with moderate to severe psoriasis of tertiary medical centers in Italy, in which response was found to be significantly affected by smoking, and incidence of psoriatic arthritis.

More patients with moderate-to-severe psoriasis were found to be early responders to ixekizumab vs ustekinumab; all those who achieved early response were associated with stable skin clearance long-term.

Poor agreement was identified regarding MRI- and classification-defined axial spondyloarthritis (axSpA) and inflammatory back pain diagnoses in patients with psoriatic disease.

Psoriasis developed in 1 in 4 patients with axial spondyloarthritis (axSpA) across a 6-year span, in which those with both conditions reported greater joint involvement and biologic use than those with only axSpA.

Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, discusses treatment considerations for patients with different types of pustular psoriasis.

Psoriasis Area and Severity Index scores indicated that patients with moderate-to-severe psoriasis had improved skin clearance when treated with risankizumab compared with secukinumab treatment.

Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, speaks on cytokines involved in the pathophysiology in pustular psoriasis and off-label therapy use.

Patients with psoriatic disease and dermatologists reported their preferred strategies to improve cardiovascular disease risk management, with a specialist-led model of care touted by both groups.

The panel closes the program with giving their final thoughts on individualizing therapies for plaque psoriasis and metabolic syndrome in specific patient subpopulations.

Drs Lebwohl and Groves list support services to help with patient adherence.

Bhavesh Shah, PharmD, explains how lower volume agents can be beneficial when treating plaque psoriasis and metabolic syndrome.

Patients with comorbid psoriasis and psoriatic arthritis exhibited significantly higher rates of depression and anxiety vs those with psoriasis alone, whereas lifetime suicidality prevalence was not different between the 2 groups but still heightened compared with the general population.

Patients with psoriasis exhibited superior efficacy outcomes when treated with ultraviolet (UV)-based phototherapy plus other adjuvant therapies vs UV monotherapy, with similar safety profiles shown for both approaches.

Robert Groves, MD, and Bhavesh Shah, PharmD, comment on the role real-world evidence plays in creating cost/value analyses for psoriasis and metabolic syndrome.

Dr Groves discusses the impact of population health knowledge in patients with metabolic syndrome.